# Letter by Wu et al Regarding Article, “G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice”.

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/diabetic-heart-disease-cannabinoid-receptor-grk3-research/
> **Published:** 2026-04-29T05:02:51-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T09:59:28-04:00
> **Clinical Summary:** New research reveals how diabetes disrupts cannabinoid receptor function in the heart through GRK3 phosphorylation, potentially worsening cardiac complications.

---

CED Clinical Relevance  #56Monitored Relevance
Evidence Brief | CED ClinicResearchers identify molecular mechanism by which cannabinoid receptor 2 phosphorylation may worsen diabetic heart injury through G protein-coupled receptor kinase 3.
DiabetesCardiovascularCb2Molecular MechanismHeart Disease

Researchers identify molecular mechanism by which cannabinoid receptor 2 phosphorylation may worsen diabetic heart injury through G protein-coupled receptor kinase 3.

What This Study Teaches Us

This correspondence identifies a specific molecular pathway where G protein-coupled receptor kinase 3 directly phosphorylates the cannabinoid receptor 2, potentially contributing to diabetic heart injury. The finding provides mechanistic insight into how endocannabinoid signaling may be dysregulated in diabetic cardiovascular disease.

Why This Matters
Understanding [CB2 receptor](https://cedclinic.com/s-caryophyllene-a-terpine-found-in-cannabis-demonstrates-therapeutic-potential-in-a-mouse-model-of-ms/) phosphorylation mechanisms could inform therapeutic approaches for diabetic cardiovascular complications. This molecular pathway may represent a target for interventions aimed at preserving endocannabinoid signaling in diabetic patients with heart disease.

Study Snapshot

Study Type
Letter/Commentary

Population
Human participants and mouse models with diabetic heart conditions

Intervention
Investigation of G protein-coupled receptor kinase 3 phosphorylation of cannabinoid receptor 2

Comparator
Not specified in abstract

Primary Outcome
Molecular mechanism of diabetic heart injury exacerbation

Key Finding
GRK3 directly phosphorylates [CB2 receptor](https://cedclinic.com/s-caryophyllene-a-terpine-found-in-cannabis-demonstrates-therapeutic-potential-in-a-mouse-model-of-ms/), potentially worsening diabetic cardiac outcomes

Journal
Circulation

Year
2024

Clinical Bottom Line
The identification of GRK3-mediated CB2 phosphorylation as a mechanism in diabetic heart injury adds to our understanding of [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) dysfunction in diabetes. However, this mechanistic finding requires validation in larger clinical studies before informing therapeutic decisions.

What This Paper Does Not Show
As a letter commenting on previous research, this communication does not provide new clinical trial data or demonstrate therapeutic efficacy of targeting this pathway. The clinical relevance and therapeutic potential of modulating GRK3-CB2 interactions remains to be established.

Where This Paper Deserves Skepticism
This appears to be correspondence rather than original research, limiting the depth of methodological evaluation possible. The translation from molecular mechanism to clinical therapeutic target requires substantial additional investigation and validation.

Dr. Caplan's Take
While interesting mechanistically, I need to see the actual research data and methodology before drawing clinical conclusions. Letters and commentaries, while valuable for scientific discourse, don’t provide the rigor needed to change practice patterns or patient counseling about cannabinoid therapies in diabetes.

What a Careful Reader Should Take Away

This work contributes to our understanding of [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) dysfunction in diabetic heart disease but represents early-stage mechanistic research. Clinical applications remain speculative until validated through controlled studies with clear therapeutic endpoints.

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

Have thoughts on this? Share it:

[X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Letter%20by%20Wu%20et%20al%20Regarding%20Article%2C%20%E2%80%9CG%20Protein-Coupled%20Receptor%20Kinase%203%20Exacerbates%20Diabetic%20Hear...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fdiabetic-heart-disease-cannabinoid-receptor-grk3-research%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fdiabetic-heart-disease-cannabinoid-receptor-grk3-research%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Letter%20by%20Wu%20et%20al%20Regarding%20Article%2C%20%E2%80%9CG%20Protein-Coupled%20Receptor%20Kinase%203%20Exacerbates%20Diabetic%20Hear...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fdiabetic-heart-disease-cannabinoid-receptor-grk3-research%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/)

Table of Contents

- [FAQ](#FAQ)[What is the role of cannabinoid receptor 2 (CB2) in diabetic heart disease?](#What_is_the_role_of_cannabinoid_receptor_2_CB2_in_diabetic_heart_disease)
- [How does G protein-coupled receptor kinase 3 affect heart function in diabetes?](#How_does_G_protein-coupled_receptor_kinase_3_affect_heart_function_in_diabetes)
- [Could targeting CB2 receptors be a therapeutic strategy for diabetic heart disease?](#Could_targeting_CB2_receptors_be_a_therapeutic_strategy_for_diabetic_heart_disease)
- [What are the clinical implications of this CB2-GRK3 interaction for diabetic patients?](#What_are_the_clinical_implications_of_this_CB2-GRK3_interaction_for_diabetic_patients)
- [How might this research impact current diabetes and cardiovascular care?](#How_might_this_research_impact_current_diabetes_and_cardiovascular_care)
- [Related](#Related)

## FAQ

#### What is the role of cannabinoid receptor 2 (CB2) in diabetic heart disease?

Research indicates that CB2 receptor phosphorylation by G protein-coupled receptor kinase 3 (GRK3) may worsen diabetic heart injuries. This suggests CB2 plays a significant role in the cardiovascular complications of diabetes through specific molecular mechanisms.

#### How does G protein-coupled receptor kinase 3 affect heart function in diabetes?

GRK3 directly phosphorylates [CB2 receptors](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/), which appears to exacerbate diabetic heart injuries. This phosphorylation process represents a key molecular pathway through which diabetic cardiovascular complications may develop or worsen.

#### Could targeting CB2 receptors be a therapeutic strategy for diabetic heart disease?

The identification of CB2 receptor phosphorylation as a mechanism worsening diabetic heart injury suggests potential therapeutic targets. However, this research is still in early stages and requires further clinical studies to determine therapeutic applications.

#### What are the clinical implications of this CB2-GRK3 interaction for diabetic patients?

Understanding this molecular mechanism may help explain why some diabetic patients develop more severe cardiovascular complications. This knowledge could potentially lead to better risk stratification and targeted treatments for diabetic heart disease.

#### How might this research impact current diabetes and cardiovascular care?

While this represents important mechanistic understanding, immediate [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) changes are not indicated. The research provides foundational knowledge that may inform future [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) and personalized treatment approaches for diabetic cardiovascular complications.

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).